Handelsavisen
prelaunch
Companies Healthcare 9955.HK
99
9955.HK HKEX Medical Equipment, Supplies & Distribution

9955.Hk

HK$0,61
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-57,6 %
ROE
-168,5 %
Net margin
-56,9 %
Debt / equity
0,53
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the healthcare services and equipment industry, providing medical equipment, supplies, and distribution services, primarily generating revenue through the sale and distribution of medical products.

Business. The company operates in the healthcare services and equipment industry, providing medical equipment, supplies, and distribution services, primarily generating revenue through the sale and distribution of medical products.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-168,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 9955.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 9955.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare services and equipment industry, providing medical equipment, supplies, and distribution services, primarily generating revenue through the sale and distribution of medical products.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    The company's capital structure shows a debt-to-equity ratio of 0.53, indicating a moderate reliance on debt financing. However, its liquidity position is constrained, with a current ratio of 1.03, suggesting limited short-term liquidity to cover immediate obligations. The company's cash and equivalents amount to 267.6 million CNY, but this is offset by long-term debt of 288.6 million CNY, resulting in a net cash position that is negative.

    Profitability metrics are weak, with a return on equity of -1.68 and a return on assets of -0.55, both significantly below industry norms. The company reported a net loss of 924.2 million CNY and an operating loss of 934.2 million CNY, indicating a challenging operating environment and potential inefficiencies in cost management.

    The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of risk or growth potential in specific areas. However, the lack of detailed segment reporting suggests a potentially concentrated business model, which could increase vulnerability to market or regulatory shifts.

    Looking ahead, the company is expected to face continued financial pressure, with no clear indication of a turnaround in the near term. The operating and net losses suggest a need for significant operational or strategic changes to restore profitability. The absence of positive revenue growth or margin improvement in the data implies a challenging outlook for the current fiscal year.

    The company's risk profile is elevated, with a medium liquidity risk and a negative net cash position. While dilution risk is currently assessed as low, the company's financial performance and capital structure suggest a potential need for additional financing in the future, which could lead to share dilution. The adjustments applied in the valuation process reflect the company's weak financial position and the associated risks.

    Recent financial filings and disclosures indicate a deteriorating financial position, with significant losses and a negative return on equity. The company has not disclosed any major strategic initiatives or operational improvements in the latest filings, which may raise concerns about its ability to address its financial challenges. The lack of positive developments in the recent transcripts and filings suggests a need for further monitoring of the company's strategic direction and financial health.

    Key takeaways
    • The company is operating at a significant loss, with a net income of -924.2 million CNY and an operating income of -934.2 million CNY.
    • The company's liquidity position is weak, with a current ratio of 1.03 and a negative net cash position after accounting for long-term debt.
    • Profitability metrics are poor, with a return on equity of -1.68 and a return on assets of -0.55, both well below industry norms.
    • The company's financial performance suggests a need for significant operational or strategic changes to restore profitability and improve liquidity.
    • The company's risk profile is elevated, with medium liquidity risk and a potential need for additional financing in the future.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$0,61
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    HK$548.6M
    Net cash
    -HK$21.0M
    Current ratio
    1.0
    Debt / equity
    0.5
    ROA
    -54.9%
    ROE
    -1.7%
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-57,6 %Bottom quartile
    Net Margin-56,9 %Bottom quartile
    ROE-168,5 %Bottom quartile
    D/E0,53Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Return On Assets
      net_income / total_assets
    Source documents
    • 9955.HK Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    9955.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage